Sionna Therapeutics, Inc. (NASDAQ:SION) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have been assigned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $45.4286.

SION has been the topic of several research reports. BTIG Research reiterated a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a report on Wednesday, January 14th. Royal Bank Of Canada reaffirmed an “underperform” rating and issued a $24.00 target price on shares of Sionna Therapeutics in a research report on Monday, December 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Lifesci Capital began coverage on Sionna Therapeutics in a research note on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 price objective for the company. Finally, Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th.

Insider Buying and Selling at Sionna Therapeutics

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 94,583 shares of the firm’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $44.54, for a total value of $4,212,726.82. Following the transaction, the director directly owned 3,610,376 shares of the company’s stock, valued at approximately $160,806,147.04. This trade represents a 2.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. sold 81,987 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $40.59, for a total transaction of $3,327,852.33. Following the sale, the director directly owned 184,619 shares of the company’s stock, valued at approximately $7,493,685.21. The trade was a 30.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 703,275 shares of company stock worth $29,467,911. Corporate insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in shares of Sionna Therapeutics in the fourth quarter valued at approximately $36,000. Russell Investments Group Ltd. purchased a new stake in Sionna Therapeutics in the 3rd quarter valued at $30,000. BNP Paribas Financial Markets bought a new position in Sionna Therapeutics during the 2nd quarter valued at $31,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Sionna Therapeutics during the 4th quarter worth $89,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Sionna Therapeutics in the 2nd quarter worth $45,000.

Sionna Therapeutics Stock Performance

Shares of SION stock opened at $42.26 on Friday. Sionna Therapeutics has a fifty-two week low of $7.26 and a fifty-two week high of $45.00. The stock has a 50 day simple moving average of $41.46 and a two-hundred day simple moving average of $32.17. The company has a market cap of $1.89 billion and a P/E ratio of -8.68.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.